Global Postmenopausal Vaginal Atrophy Drugs Supply, Demand and Key Producers, 2023-2029
The global Postmenopausal Vaginal Atrophy Drugs market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).
Postmenopausal vaginal atrophy (PVA) is the type of condition of vaginal wall thinning the reduced level of estrogen causes that. The changes in the genitourinary tract arising from a hypoestrogenic state includes decreased vaginal vascularization, reduced vaginal lubrication, thinning of the vaginal epithelium. The pH level continuously increases and loss of lactobacilli microflora allows opportunistic colonization by pathogenic bacteria can produce infection.
This report studies the global Postmenopausal Vaginal Atrophy Drugs production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Postmenopausal Vaginal Atrophy Drugs, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Postmenopausal Vaginal Atrophy Drugs that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Postmenopausal Vaginal Atrophy Drugs total production and demand, 2018-2029, (K Units)
Global Postmenopausal Vaginal Atrophy Drugs total production value, 2018-2029, (USD Million)
Global Postmenopausal Vaginal Atrophy Drugs production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Postmenopausal Vaginal Atrophy Drugs consumption by region & country, CAGR, 2018-2029 & (K Units)
U.S. VS China: Postmenopausal Vaginal Atrophy Drugs domestic production, consumption, key domestic manufacturers and share
Global Postmenopausal Vaginal Atrophy Drugs production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)
Global Postmenopausal Vaginal Atrophy Drugs production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Postmenopausal Vaginal Atrophy Drugs production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units)
This reports profiles key players in the global Postmenopausal Vaginal Atrophy Drugs market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer Inc, Mylan NV, Novartis AG, Hikma Pharmaceuticals plc, Aurobindo Pharma, AbbVie Inc, Melinta Therapeutics, Inc, Bristol-Myers Squibb Company and GSK plc, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Postmenopausal Vaginal Atrophy Drugs market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Postmenopausal Vaginal Atrophy Drugs Market, By Region:
1. How big is the global Postmenopausal Vaginal Atrophy Drugs market?
2. What is the demand of the global Postmenopausal Vaginal Atrophy Drugs market?
3. What is the year over year growth of the global Postmenopausal Vaginal Atrophy Drugs market?
4. What is the production and production value of the global Postmenopausal Vaginal Atrophy Drugs market?
5. Who are the key producers in the global Postmenopausal Vaginal Atrophy Drugs market?
6. What are the growth factors driving the market demand?
Postmenopausal vaginal atrophy (PVA) is the type of condition of vaginal wall thinning the reduced level of estrogen causes that. The changes in the genitourinary tract arising from a hypoestrogenic state includes decreased vaginal vascularization, reduced vaginal lubrication, thinning of the vaginal epithelium. The pH level continuously increases and loss of lactobacilli microflora allows opportunistic colonization by pathogenic bacteria can produce infection.
This report studies the global Postmenopausal Vaginal Atrophy Drugs production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Postmenopausal Vaginal Atrophy Drugs, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Postmenopausal Vaginal Atrophy Drugs that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Postmenopausal Vaginal Atrophy Drugs total production and demand, 2018-2029, (K Units)
Global Postmenopausal Vaginal Atrophy Drugs total production value, 2018-2029, (USD Million)
Global Postmenopausal Vaginal Atrophy Drugs production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Postmenopausal Vaginal Atrophy Drugs consumption by region & country, CAGR, 2018-2029 & (K Units)
U.S. VS China: Postmenopausal Vaginal Atrophy Drugs domestic production, consumption, key domestic manufacturers and share
Global Postmenopausal Vaginal Atrophy Drugs production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)
Global Postmenopausal Vaginal Atrophy Drugs production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Postmenopausal Vaginal Atrophy Drugs production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units)
This reports profiles key players in the global Postmenopausal Vaginal Atrophy Drugs market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer Inc, Mylan NV, Novartis AG, Hikma Pharmaceuticals plc, Aurobindo Pharma, AbbVie Inc, Melinta Therapeutics, Inc, Bristol-Myers Squibb Company and GSK plc, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Postmenopausal Vaginal Atrophy Drugs market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Postmenopausal Vaginal Atrophy Drugs Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Topical Estrogen
- Oral Estrogen
- Other
- Online Pharmacy
- Hospital Pharmacy
- Pfizer Inc
- Mylan NV
- Novartis AG
- Hikma Pharmaceuticals plc
- Aurobindo Pharma
- AbbVie Inc
- Melinta Therapeutics, Inc
- Bristol-Myers Squibb Company
- GSK plc
- Bayer AG
- Lupin
- Perrigo Company plc
- Bionovo, Inc
- TherapeuticsMD, Inc
- Endoceutics, Inc
1. How big is the global Postmenopausal Vaginal Atrophy Drugs market?
2. What is the demand of the global Postmenopausal Vaginal Atrophy Drugs market?
3. What is the year over year growth of the global Postmenopausal Vaginal Atrophy Drugs market?
4. What is the production and production value of the global Postmenopausal Vaginal Atrophy Drugs market?
5. Who are the key producers in the global Postmenopausal Vaginal Atrophy Drugs market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Postmenopausal Vaginal Atrophy Drugs Introduction
1.2 World Postmenopausal Vaginal Atrophy Drugs Supply & Forecast
1.2.1 World Postmenopausal Vaginal Atrophy Drugs Production Value (2018 & 2022 & 2029)
1.2.2 World Postmenopausal Vaginal Atrophy Drugs Production (2018-2029)
1.2.3 World Postmenopausal Vaginal Atrophy Drugs Pricing Trends (2018-2029)
1.3 World Postmenopausal Vaginal Atrophy Drugs Production by Region (Based on Production Site)
1.3.1 World Postmenopausal Vaginal Atrophy Drugs Production Value by Region (2018-2029)
1.3.2 World Postmenopausal Vaginal Atrophy Drugs Production by Region (2018-2029)
1.3.3 World Postmenopausal Vaginal Atrophy Drugs Average Price by Region (2018-2029)
1.3.4 North America Postmenopausal Vaginal Atrophy Drugs Production (2018-2029)
1.3.5 Europe Postmenopausal Vaginal Atrophy Drugs Production (2018-2029)
1.3.6 China Postmenopausal Vaginal Atrophy Drugs Production (2018-2029)
1.3.7 Japan Postmenopausal Vaginal Atrophy Drugs Production (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Postmenopausal Vaginal Atrophy Drugs Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Postmenopausal Vaginal Atrophy Drugs Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Postmenopausal Vaginal Atrophy Drugs Demand (2018-2029)
2.2 World Postmenopausal Vaginal Atrophy Drugs Consumption by Region
2.2.1 World Postmenopausal Vaginal Atrophy Drugs Consumption by Region (2018-2023)
2.2.2 World Postmenopausal Vaginal Atrophy Drugs Consumption Forecast by Region (2024-2029)
2.3 United States Postmenopausal Vaginal Atrophy Drugs Consumption (2018-2029)
2.4 China Postmenopausal Vaginal Atrophy Drugs Consumption (2018-2029)
2.5 Europe Postmenopausal Vaginal Atrophy Drugs Consumption (2018-2029)
2.6 Japan Postmenopausal Vaginal Atrophy Drugs Consumption (2018-2029)
2.7 South Korea Postmenopausal Vaginal Atrophy Drugs Consumption (2018-2029)
2.8 ASEAN Postmenopausal Vaginal Atrophy Drugs Consumption (2018-2029)
2.9 India Postmenopausal Vaginal Atrophy Drugs Consumption (2018-2029)
3 WORLD POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Postmenopausal Vaginal Atrophy Drugs Production Value by Manufacturer (2018-2023)
3.2 World Postmenopausal Vaginal Atrophy Drugs Production by Manufacturer (2018-2023)
3.3 World Postmenopausal Vaginal Atrophy Drugs Average Price by Manufacturer (2018-2023)
3.4 Postmenopausal Vaginal Atrophy Drugs Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Postmenopausal Vaginal Atrophy Drugs Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Postmenopausal Vaginal Atrophy Drugs in 2022
3.5.3 Global Concentration Ratios (CR8) for Postmenopausal Vaginal Atrophy Drugs in 2022
3.6 Postmenopausal Vaginal Atrophy Drugs Market: Overall Company Footprint Analysis
3.6.1 Postmenopausal Vaginal Atrophy Drugs Market: Region Footprint
3.6.2 Postmenopausal Vaginal Atrophy Drugs Market: Company Product Type Footprint
3.6.3 Postmenopausal Vaginal Atrophy Drugs Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Postmenopausal Vaginal Atrophy Drugs Production Value Comparison
4.1.1 United States VS China: Postmenopausal Vaginal Atrophy Drugs Production Value Comparison (2018 & 2022 & 2029)
4.1.2 United States VS China: Postmenopausal Vaginal Atrophy Drugs Production Value Market Share Comparison (2018 & 2022 & 2029)
4.2 United States VS China: Postmenopausal Vaginal Atrophy Drugs Production Comparison
4.2.1 United States VS China: Postmenopausal Vaginal Atrophy Drugs Production Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Postmenopausal Vaginal Atrophy Drugs Production Market Share Comparison (2018 & 2022 & 2029)
4.3 United States VS China: Postmenopausal Vaginal Atrophy Drugs Consumption Comparison
4.3.1 United States VS China: Postmenopausal Vaginal Atrophy Drugs Consumption Comparison (2018 & 2022 & 2029)
4.3.2 United States VS China: Postmenopausal Vaginal Atrophy Drugs Consumption Market Share Comparison (2018 & 2022 & 2029)
4.4 United States Based Postmenopausal Vaginal Atrophy Drugs Manufacturers and Market Share, 2018-2023
4.4.1 United States Based Postmenopausal Vaginal Atrophy Drugs Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Postmenopausal Vaginal Atrophy Drugs Production Value (2018-2023)
4.4.3 United States Based Manufacturers Postmenopausal Vaginal Atrophy Drugs Production (2018-2023)
4.5 China Based Postmenopausal Vaginal Atrophy Drugs Manufacturers and Market Share
4.5.1 China Based Postmenopausal Vaginal Atrophy Drugs Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Postmenopausal Vaginal Atrophy Drugs Production Value (2018-2023)
4.5.3 China Based Manufacturers Postmenopausal Vaginal Atrophy Drugs Production (2018-2023)
4.6 Rest of World Based Postmenopausal Vaginal Atrophy Drugs Manufacturers and Market Share, 2018-2023
4.6.1 Rest of World Based Postmenopausal Vaginal Atrophy Drugs Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Postmenopausal Vaginal Atrophy Drugs Production Value (2018-2023)
4.6.3 Rest of World Based Manufacturers Postmenopausal Vaginal Atrophy Drugs Production (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Postmenopausal Vaginal Atrophy Drugs Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Topical Estrogen
5.2.2 Oral Estrogen
5.2.3 Other
5.3 Market Segment by Type
5.3.1 World Postmenopausal Vaginal Atrophy Drugs Production by Type (2018-2029)
5.3.2 World Postmenopausal Vaginal Atrophy Drugs Production Value by Type (2018-2029)
5.3.3 World Postmenopausal Vaginal Atrophy Drugs Average Price by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Postmenopausal Vaginal Atrophy Drugs Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Online Pharmacy
6.2.2 Hospital Pharmacy
6.3 Market Segment by Application
6.3.1 World Postmenopausal Vaginal Atrophy Drugs Production by Application (2018-2029)
6.3.2 World Postmenopausal Vaginal Atrophy Drugs Production Value by Application (2018-2029)
6.3.3 World Postmenopausal Vaginal Atrophy Drugs Average Price by Application (2018-2029)
7 COMPANY PROFILES
7.1 Pfizer Inc
7.1.1 Pfizer Inc Details
7.1.2 Pfizer Inc Major Business
7.1.3 Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
7.1.4 Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.1.5 Pfizer Inc Recent Developments/Updates
7.1.6 Pfizer Inc Competitive Strengths & Weaknesses
7.2 Mylan NV
7.2.1 Mylan NV Details
7.2.2 Mylan NV Major Business
7.2.3 Mylan NV Postmenopausal Vaginal Atrophy Drugs Product and Services
7.2.4 Mylan NV Postmenopausal Vaginal Atrophy Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.2.5 Mylan NV Recent Developments/Updates
7.2.6 Mylan NV Competitive Strengths & Weaknesses
7.3 Novartis AG
7.3.1 Novartis AG Details
7.3.2 Novartis AG Major Business
7.3.3 Novartis AG Postmenopausal Vaginal Atrophy Drugs Product and Services
7.3.4 Novartis AG Postmenopausal Vaginal Atrophy Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.3.5 Novartis AG Recent Developments/Updates
7.3.6 Novartis AG Competitive Strengths & Weaknesses
7.4 Hikma Pharmaceuticals plc
7.4.1 Hikma Pharmaceuticals plc Details
7.4.2 Hikma Pharmaceuticals plc Major Business
7.4.3 Hikma Pharmaceuticals plc Postmenopausal Vaginal Atrophy Drugs Product and Services
7.4.4 Hikma Pharmaceuticals plc Postmenopausal Vaginal Atrophy Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.4.5 Hikma Pharmaceuticals plc Recent Developments/Updates
7.4.6 Hikma Pharmaceuticals plc Competitive Strengths & Weaknesses
7.5 Aurobindo Pharma
7.5.1 Aurobindo Pharma Details
7.5.2 Aurobindo Pharma Major Business
7.5.3 Aurobindo Pharma Postmenopausal Vaginal Atrophy Drugs Product and Services
7.5.4 Aurobindo Pharma Postmenopausal Vaginal Atrophy Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.5.5 Aurobindo Pharma Recent Developments/Updates
7.5.6 Aurobindo Pharma Competitive Strengths & Weaknesses
7.6 AbbVie Inc
7.6.1 AbbVie Inc Details
7.6.2 AbbVie Inc Major Business
7.6.3 AbbVie Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
7.6.4 AbbVie Inc Postmenopausal Vaginal Atrophy Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.6.5 AbbVie Inc Recent Developments/Updates
7.6.6 AbbVie Inc Competitive Strengths & Weaknesses
7.7 Melinta Therapeutics, Inc
7.7.1 Melinta Therapeutics, Inc Details
7.7.2 Melinta Therapeutics, Inc Major Business
7.7.3 Melinta Therapeutics, Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
7.7.4 Melinta Therapeutics, Inc Postmenopausal Vaginal Atrophy Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.7.5 Melinta Therapeutics, Inc Recent Developments/Updates
7.7.6 Melinta Therapeutics, Inc Competitive Strengths & Weaknesses
7.8 Bristol-Myers Squibb Company
7.8.1 Bristol-Myers Squibb Company Details
7.8.2 Bristol-Myers Squibb Company Major Business
7.8.3 Bristol-Myers Squibb Company Postmenopausal Vaginal Atrophy Drugs Product and Services
7.8.4 Bristol-Myers Squibb Company Postmenopausal Vaginal Atrophy Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.8.5 Bristol-Myers Squibb Company Recent Developments/Updates
7.8.6 Bristol-Myers Squibb Company Competitive Strengths & Weaknesses
7.9 GSK plc
7.9.1 GSK plc Details
7.9.2 GSK plc Major Business
7.9.3 GSK plc Postmenopausal Vaginal Atrophy Drugs Product and Services
7.9.4 GSK plc Postmenopausal Vaginal Atrophy Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.9.5 GSK plc Recent Developments/Updates
7.9.6 GSK plc Competitive Strengths & Weaknesses
7.10 Bayer AG
7.10.1 Bayer AG Details
7.10.2 Bayer AG Major Business
7.10.3 Bayer AG Postmenopausal Vaginal Atrophy Drugs Product and Services
7.10.4 Bayer AG Postmenopausal Vaginal Atrophy Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.10.5 Bayer AG Recent Developments/Updates
7.10.6 Bayer AG Competitive Strengths & Weaknesses
7.11 Lupin
7.11.1 Lupin Details
7.11.2 Lupin Major Business
7.11.3 Lupin Postmenopausal Vaginal Atrophy Drugs Product and Services
7.11.4 Lupin Postmenopausal Vaginal Atrophy Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.11.5 Lupin Recent Developments/Updates
7.11.6 Lupin Competitive Strengths & Weaknesses
7.12 Perrigo Company plc
7.12.1 Perrigo Company plc Details
7.12.2 Perrigo Company plc Major Business
7.12.3 Perrigo Company plc Postmenopausal Vaginal Atrophy Drugs Product and Services
7.12.4 Perrigo Company plc Postmenopausal Vaginal Atrophy Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.12.5 Perrigo Company plc Recent Developments/Updates
7.12.6 Perrigo Company plc Competitive Strengths & Weaknesses
7.13 Bionovo, Inc
7.13.1 Bionovo, Inc Details
7.13.2 Bionovo, Inc Major Business
7.13.3 Bionovo, Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
7.13.4 Bionovo, Inc Postmenopausal Vaginal Atrophy Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.13.5 Bionovo, Inc Recent Developments/Updates
7.13.6 Bionovo, Inc Competitive Strengths & Weaknesses
7.14 TherapeuticsMD, Inc
7.14.1 TherapeuticsMD, Inc Details
7.14.2 TherapeuticsMD, Inc Major Business
7.14.3 TherapeuticsMD, Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
7.14.4 TherapeuticsMD, Inc Postmenopausal Vaginal Atrophy Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.14.5 TherapeuticsMD, Inc Recent Developments/Updates
7.14.6 TherapeuticsMD, Inc Competitive Strengths & Weaknesses
7.15 Endoceutics, Inc
7.15.1 Endoceutics, Inc Details
7.15.2 Endoceutics, Inc Major Business
7.15.3 Endoceutics, Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
7.15.4 Endoceutics, Inc Postmenopausal Vaginal Atrophy Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.15.5 Endoceutics, Inc Recent Developments/Updates
7.15.6 Endoceutics, Inc Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Postmenopausal Vaginal Atrophy Drugs Industry Chain
8.2 Postmenopausal Vaginal Atrophy Drugs Upstream Analysis
8.2.1 Postmenopausal Vaginal Atrophy Drugs Core Raw Materials
8.2.2 Main Manufacturers of Postmenopausal Vaginal Atrophy Drugs Core Raw Materials
8.3 Midstream Analysis
8.4 Downstream Analysis
8.5 Postmenopausal Vaginal Atrophy Drugs Production Mode
8.6 Postmenopausal Vaginal Atrophy Drugs Procurement Model
8.7 Postmenopausal Vaginal Atrophy Drugs Industry Sales Model and Sales Channels
8.7.1 Postmenopausal Vaginal Atrophy Drugs Sales Model
8.7.2 Postmenopausal Vaginal Atrophy Drugs Typical Customers
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Postmenopausal Vaginal Atrophy Drugs Introduction
1.2 World Postmenopausal Vaginal Atrophy Drugs Supply & Forecast
1.2.1 World Postmenopausal Vaginal Atrophy Drugs Production Value (2018 & 2022 & 2029)
1.2.2 World Postmenopausal Vaginal Atrophy Drugs Production (2018-2029)
1.2.3 World Postmenopausal Vaginal Atrophy Drugs Pricing Trends (2018-2029)
1.3 World Postmenopausal Vaginal Atrophy Drugs Production by Region (Based on Production Site)
1.3.1 World Postmenopausal Vaginal Atrophy Drugs Production Value by Region (2018-2029)
1.3.2 World Postmenopausal Vaginal Atrophy Drugs Production by Region (2018-2029)
1.3.3 World Postmenopausal Vaginal Atrophy Drugs Average Price by Region (2018-2029)
1.3.4 North America Postmenopausal Vaginal Atrophy Drugs Production (2018-2029)
1.3.5 Europe Postmenopausal Vaginal Atrophy Drugs Production (2018-2029)
1.3.6 China Postmenopausal Vaginal Atrophy Drugs Production (2018-2029)
1.3.7 Japan Postmenopausal Vaginal Atrophy Drugs Production (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Postmenopausal Vaginal Atrophy Drugs Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Postmenopausal Vaginal Atrophy Drugs Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Postmenopausal Vaginal Atrophy Drugs Demand (2018-2029)
2.2 World Postmenopausal Vaginal Atrophy Drugs Consumption by Region
2.2.1 World Postmenopausal Vaginal Atrophy Drugs Consumption by Region (2018-2023)
2.2.2 World Postmenopausal Vaginal Atrophy Drugs Consumption Forecast by Region (2024-2029)
2.3 United States Postmenopausal Vaginal Atrophy Drugs Consumption (2018-2029)
2.4 China Postmenopausal Vaginal Atrophy Drugs Consumption (2018-2029)
2.5 Europe Postmenopausal Vaginal Atrophy Drugs Consumption (2018-2029)
2.6 Japan Postmenopausal Vaginal Atrophy Drugs Consumption (2018-2029)
2.7 South Korea Postmenopausal Vaginal Atrophy Drugs Consumption (2018-2029)
2.8 ASEAN Postmenopausal Vaginal Atrophy Drugs Consumption (2018-2029)
2.9 India Postmenopausal Vaginal Atrophy Drugs Consumption (2018-2029)
3 WORLD POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Postmenopausal Vaginal Atrophy Drugs Production Value by Manufacturer (2018-2023)
3.2 World Postmenopausal Vaginal Atrophy Drugs Production by Manufacturer (2018-2023)
3.3 World Postmenopausal Vaginal Atrophy Drugs Average Price by Manufacturer (2018-2023)
3.4 Postmenopausal Vaginal Atrophy Drugs Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Postmenopausal Vaginal Atrophy Drugs Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Postmenopausal Vaginal Atrophy Drugs in 2022
3.5.3 Global Concentration Ratios (CR8) for Postmenopausal Vaginal Atrophy Drugs in 2022
3.6 Postmenopausal Vaginal Atrophy Drugs Market: Overall Company Footprint Analysis
3.6.1 Postmenopausal Vaginal Atrophy Drugs Market: Region Footprint
3.6.2 Postmenopausal Vaginal Atrophy Drugs Market: Company Product Type Footprint
3.6.3 Postmenopausal Vaginal Atrophy Drugs Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Postmenopausal Vaginal Atrophy Drugs Production Value Comparison
4.1.1 United States VS China: Postmenopausal Vaginal Atrophy Drugs Production Value Comparison (2018 & 2022 & 2029)
4.1.2 United States VS China: Postmenopausal Vaginal Atrophy Drugs Production Value Market Share Comparison (2018 & 2022 & 2029)
4.2 United States VS China: Postmenopausal Vaginal Atrophy Drugs Production Comparison
4.2.1 United States VS China: Postmenopausal Vaginal Atrophy Drugs Production Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Postmenopausal Vaginal Atrophy Drugs Production Market Share Comparison (2018 & 2022 & 2029)
4.3 United States VS China: Postmenopausal Vaginal Atrophy Drugs Consumption Comparison
4.3.1 United States VS China: Postmenopausal Vaginal Atrophy Drugs Consumption Comparison (2018 & 2022 & 2029)
4.3.2 United States VS China: Postmenopausal Vaginal Atrophy Drugs Consumption Market Share Comparison (2018 & 2022 & 2029)
4.4 United States Based Postmenopausal Vaginal Atrophy Drugs Manufacturers and Market Share, 2018-2023
4.4.1 United States Based Postmenopausal Vaginal Atrophy Drugs Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Postmenopausal Vaginal Atrophy Drugs Production Value (2018-2023)
4.4.3 United States Based Manufacturers Postmenopausal Vaginal Atrophy Drugs Production (2018-2023)
4.5 China Based Postmenopausal Vaginal Atrophy Drugs Manufacturers and Market Share
4.5.1 China Based Postmenopausal Vaginal Atrophy Drugs Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Postmenopausal Vaginal Atrophy Drugs Production Value (2018-2023)
4.5.3 China Based Manufacturers Postmenopausal Vaginal Atrophy Drugs Production (2018-2023)
4.6 Rest of World Based Postmenopausal Vaginal Atrophy Drugs Manufacturers and Market Share, 2018-2023
4.6.1 Rest of World Based Postmenopausal Vaginal Atrophy Drugs Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Postmenopausal Vaginal Atrophy Drugs Production Value (2018-2023)
4.6.3 Rest of World Based Manufacturers Postmenopausal Vaginal Atrophy Drugs Production (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Postmenopausal Vaginal Atrophy Drugs Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Topical Estrogen
5.2.2 Oral Estrogen
5.2.3 Other
5.3 Market Segment by Type
5.3.1 World Postmenopausal Vaginal Atrophy Drugs Production by Type (2018-2029)
5.3.2 World Postmenopausal Vaginal Atrophy Drugs Production Value by Type (2018-2029)
5.3.3 World Postmenopausal Vaginal Atrophy Drugs Average Price by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Postmenopausal Vaginal Atrophy Drugs Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Online Pharmacy
6.2.2 Hospital Pharmacy
6.3 Market Segment by Application
6.3.1 World Postmenopausal Vaginal Atrophy Drugs Production by Application (2018-2029)
6.3.2 World Postmenopausal Vaginal Atrophy Drugs Production Value by Application (2018-2029)
6.3.3 World Postmenopausal Vaginal Atrophy Drugs Average Price by Application (2018-2029)
7 COMPANY PROFILES
7.1 Pfizer Inc
7.1.1 Pfizer Inc Details
7.1.2 Pfizer Inc Major Business
7.1.3 Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
7.1.4 Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.1.5 Pfizer Inc Recent Developments/Updates
7.1.6 Pfizer Inc Competitive Strengths & Weaknesses
7.2 Mylan NV
7.2.1 Mylan NV Details
7.2.2 Mylan NV Major Business
7.2.3 Mylan NV Postmenopausal Vaginal Atrophy Drugs Product and Services
7.2.4 Mylan NV Postmenopausal Vaginal Atrophy Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.2.5 Mylan NV Recent Developments/Updates
7.2.6 Mylan NV Competitive Strengths & Weaknesses
7.3 Novartis AG
7.3.1 Novartis AG Details
7.3.2 Novartis AG Major Business
7.3.3 Novartis AG Postmenopausal Vaginal Atrophy Drugs Product and Services
7.3.4 Novartis AG Postmenopausal Vaginal Atrophy Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.3.5 Novartis AG Recent Developments/Updates
7.3.6 Novartis AG Competitive Strengths & Weaknesses
7.4 Hikma Pharmaceuticals plc
7.4.1 Hikma Pharmaceuticals plc Details
7.4.2 Hikma Pharmaceuticals plc Major Business
7.4.3 Hikma Pharmaceuticals plc Postmenopausal Vaginal Atrophy Drugs Product and Services
7.4.4 Hikma Pharmaceuticals plc Postmenopausal Vaginal Atrophy Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.4.5 Hikma Pharmaceuticals plc Recent Developments/Updates
7.4.6 Hikma Pharmaceuticals plc Competitive Strengths & Weaknesses
7.5 Aurobindo Pharma
7.5.1 Aurobindo Pharma Details
7.5.2 Aurobindo Pharma Major Business
7.5.3 Aurobindo Pharma Postmenopausal Vaginal Atrophy Drugs Product and Services
7.5.4 Aurobindo Pharma Postmenopausal Vaginal Atrophy Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.5.5 Aurobindo Pharma Recent Developments/Updates
7.5.6 Aurobindo Pharma Competitive Strengths & Weaknesses
7.6 AbbVie Inc
7.6.1 AbbVie Inc Details
7.6.2 AbbVie Inc Major Business
7.6.3 AbbVie Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
7.6.4 AbbVie Inc Postmenopausal Vaginal Atrophy Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.6.5 AbbVie Inc Recent Developments/Updates
7.6.6 AbbVie Inc Competitive Strengths & Weaknesses
7.7 Melinta Therapeutics, Inc
7.7.1 Melinta Therapeutics, Inc Details
7.7.2 Melinta Therapeutics, Inc Major Business
7.7.3 Melinta Therapeutics, Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
7.7.4 Melinta Therapeutics, Inc Postmenopausal Vaginal Atrophy Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.7.5 Melinta Therapeutics, Inc Recent Developments/Updates
7.7.6 Melinta Therapeutics, Inc Competitive Strengths & Weaknesses
7.8 Bristol-Myers Squibb Company
7.8.1 Bristol-Myers Squibb Company Details
7.8.2 Bristol-Myers Squibb Company Major Business
7.8.3 Bristol-Myers Squibb Company Postmenopausal Vaginal Atrophy Drugs Product and Services
7.8.4 Bristol-Myers Squibb Company Postmenopausal Vaginal Atrophy Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.8.5 Bristol-Myers Squibb Company Recent Developments/Updates
7.8.6 Bristol-Myers Squibb Company Competitive Strengths & Weaknesses
7.9 GSK plc
7.9.1 GSK plc Details
7.9.2 GSK plc Major Business
7.9.3 GSK plc Postmenopausal Vaginal Atrophy Drugs Product and Services
7.9.4 GSK plc Postmenopausal Vaginal Atrophy Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.9.5 GSK plc Recent Developments/Updates
7.9.6 GSK plc Competitive Strengths & Weaknesses
7.10 Bayer AG
7.10.1 Bayer AG Details
7.10.2 Bayer AG Major Business
7.10.3 Bayer AG Postmenopausal Vaginal Atrophy Drugs Product and Services
7.10.4 Bayer AG Postmenopausal Vaginal Atrophy Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.10.5 Bayer AG Recent Developments/Updates
7.10.6 Bayer AG Competitive Strengths & Weaknesses
7.11 Lupin
7.11.1 Lupin Details
7.11.2 Lupin Major Business
7.11.3 Lupin Postmenopausal Vaginal Atrophy Drugs Product and Services
7.11.4 Lupin Postmenopausal Vaginal Atrophy Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.11.5 Lupin Recent Developments/Updates
7.11.6 Lupin Competitive Strengths & Weaknesses
7.12 Perrigo Company plc
7.12.1 Perrigo Company plc Details
7.12.2 Perrigo Company plc Major Business
7.12.3 Perrigo Company plc Postmenopausal Vaginal Atrophy Drugs Product and Services
7.12.4 Perrigo Company plc Postmenopausal Vaginal Atrophy Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.12.5 Perrigo Company plc Recent Developments/Updates
7.12.6 Perrigo Company plc Competitive Strengths & Weaknesses
7.13 Bionovo, Inc
7.13.1 Bionovo, Inc Details
7.13.2 Bionovo, Inc Major Business
7.13.3 Bionovo, Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
7.13.4 Bionovo, Inc Postmenopausal Vaginal Atrophy Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.13.5 Bionovo, Inc Recent Developments/Updates
7.13.6 Bionovo, Inc Competitive Strengths & Weaknesses
7.14 TherapeuticsMD, Inc
7.14.1 TherapeuticsMD, Inc Details
7.14.2 TherapeuticsMD, Inc Major Business
7.14.3 TherapeuticsMD, Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
7.14.4 TherapeuticsMD, Inc Postmenopausal Vaginal Atrophy Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.14.5 TherapeuticsMD, Inc Recent Developments/Updates
7.14.6 TherapeuticsMD, Inc Competitive Strengths & Weaknesses
7.15 Endoceutics, Inc
7.15.1 Endoceutics, Inc Details
7.15.2 Endoceutics, Inc Major Business
7.15.3 Endoceutics, Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
7.15.4 Endoceutics, Inc Postmenopausal Vaginal Atrophy Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.15.5 Endoceutics, Inc Recent Developments/Updates
7.15.6 Endoceutics, Inc Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Postmenopausal Vaginal Atrophy Drugs Industry Chain
8.2 Postmenopausal Vaginal Atrophy Drugs Upstream Analysis
8.2.1 Postmenopausal Vaginal Atrophy Drugs Core Raw Materials
8.2.2 Main Manufacturers of Postmenopausal Vaginal Atrophy Drugs Core Raw Materials
8.3 Midstream Analysis
8.4 Downstream Analysis
8.5 Postmenopausal Vaginal Atrophy Drugs Production Mode
8.6 Postmenopausal Vaginal Atrophy Drugs Procurement Model
8.7 Postmenopausal Vaginal Atrophy Drugs Industry Sales Model and Sales Channels
8.7.1 Postmenopausal Vaginal Atrophy Drugs Sales Model
8.7.2 Postmenopausal Vaginal Atrophy Drugs Typical Customers
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Postmenopausal Vaginal Atrophy Drugs Production Value by Region (2018, 2022 and 2029) & (USD Million)
Table 2. World Postmenopausal Vaginal Atrophy Drugs Production Value by Region (2018-2023) & (USD Million)
Table 3. World Postmenopausal Vaginal Atrophy Drugs Production Value by Region (2024-2029) & (USD Million)
Table 4. World Postmenopausal Vaginal Atrophy Drugs Production Value Market Share by Region (2018-2023)
Table 5. World Postmenopausal Vaginal Atrophy Drugs Production Value Market Share by Region (2024-2029)
Table 6. World Postmenopausal Vaginal Atrophy Drugs Production by Region (2018-2023) & (K Units)
Table 7. World Postmenopausal Vaginal Atrophy Drugs Production by Region (2024-2029) & (K Units)
Table 8. World Postmenopausal Vaginal Atrophy Drugs Production Market Share by Region (2018-2023)
Table 9. World Postmenopausal Vaginal Atrophy Drugs Production Market Share by Region (2024-2029)
Table 10. World Postmenopausal Vaginal Atrophy Drugs Average Price by Region (2018-2023) & (US$/Unit)
Table 11. World Postmenopausal Vaginal Atrophy Drugs Average Price by Region (2024-2029) & (US$/Unit)
Table 12. Postmenopausal Vaginal Atrophy Drugs Major Market Trends
Table 13. World Postmenopausal Vaginal Atrophy Drugs Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)
Table 14. World Postmenopausal Vaginal Atrophy Drugs Consumption by Region (2018-2023) & (K Units)
Table 15. World Postmenopausal Vaginal Atrophy Drugs Consumption Forecast by Region (2024-2029) & (K Units)
Table 16. World Postmenopausal Vaginal Atrophy Drugs Production Value by Manufacturer (2018-2023) & (USD Million)
Table 17. Production Value Market Share of Key Postmenopausal Vaginal Atrophy Drugs Producers in 2022
Table 18. World Postmenopausal Vaginal Atrophy Drugs Production by Manufacturer (2018-2023) & (K Units)
Table 19. Production Market Share of Key Postmenopausal Vaginal Atrophy Drugs Producers in 2022
Table 20. World Postmenopausal Vaginal Atrophy Drugs Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 21. Global Postmenopausal Vaginal Atrophy Drugs Company Evaluation Quadrant
Table 22. World Postmenopausal Vaginal Atrophy Drugs Industry Rank of Major Manufacturers, Based on Production Value in 2022
Table 23. Head Office and Postmenopausal Vaginal Atrophy Drugs Production Site of Key Manufacturer
Table 24. Postmenopausal Vaginal Atrophy Drugs Market: Company Product Type Footprint
Table 25. Postmenopausal Vaginal Atrophy Drugs Market: Company Product Application Footprint
Table 26. Postmenopausal Vaginal Atrophy Drugs Competitive Factors
Table 27. Postmenopausal Vaginal Atrophy Drugs New Entrant and Capacity Expansion Plans
Table 28. Postmenopausal Vaginal Atrophy Drugs Mergers & Acquisitions Activity
Table 29. United States VS China Postmenopausal Vaginal Atrophy Drugs Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 30. United States VS China Postmenopausal Vaginal Atrophy Drugs Production Comparison, (2018 & 2022 & 2029) & (K Units)
Table 31. United States VS China Postmenopausal Vaginal Atrophy Drugs Consumption Comparison, (2018 & 2022 & 2029) & (K Units)
Table 32. United States Based Postmenopausal Vaginal Atrophy Drugs Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Postmenopausal Vaginal Atrophy Drugs Production Value, (2018-2023) & (USD Million)
Table 34. United States Based Manufacturers Postmenopausal Vaginal Atrophy Drugs Production Value Market Share (2018-2023)
Table 35. United States Based Manufacturers Postmenopausal Vaginal Atrophy Drugs Production (2018-2023) & (K Units)
Table 36. United States Based Manufacturers Postmenopausal Vaginal Atrophy Drugs Production Market Share (2018-2023)
Table 37. China Based Postmenopausal Vaginal Atrophy Drugs Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Postmenopausal Vaginal Atrophy Drugs Production Value, (2018-2023) & (USD Million)
Table 39. China Based Manufacturers Postmenopausal Vaginal Atrophy Drugs Production Value Market Share (2018-2023)
Table 40. China Based Manufacturers Postmenopausal Vaginal Atrophy Drugs Production (2018-2023) & (K Units)
Table 41. China Based Manufacturers Postmenopausal Vaginal Atrophy Drugs Production Market Share (2018-2023)
Table 42. Rest of World Based Postmenopausal Vaginal Atrophy Drugs Manufacturers, Headquarters and Production Site (States, Country)
Table 43. Rest of World Based Manufacturers Postmenopausal Vaginal Atrophy Drugs Production Value, (2018-2023) & (USD Million)
Table 44. Rest of World Based Manufacturers Postmenopausal Vaginal Atrophy Drugs Production Value Market Share (2018-2023)
Table 45. Rest of World Based Manufacturers Postmenopausal Vaginal Atrophy Drugs Production (2018-2023) & (K Units)
Table 46. Rest of World Based Manufacturers Postmenopausal Vaginal Atrophy Drugs Production Market Share (2018-2023)
Table 47. World Postmenopausal Vaginal Atrophy Drugs Production Value by Type, (USD Million), 2018 & 2022 & 2029
Table 48. World Postmenopausal Vaginal Atrophy Drugs Production by Type (2018-2023) & (K Units)
Table 49. World Postmenopausal Vaginal Atrophy Drugs Production by Type (2024-2029) & (K Units)
Table 50. World Postmenopausal Vaginal Atrophy Drugs Production Value by Type (2018-2023) & (USD Million)
Table 51. World Postmenopausal Vaginal Atrophy Drugs Production Value by Type (2024-2029) & (USD Million)
Table 52. World Postmenopausal Vaginal Atrophy Drugs Average Price by Type (2018-2023) & (US$/Unit)
Table 53. World Postmenopausal Vaginal Atrophy Drugs Average Price by Type (2024-2029) & (US$/Unit)
Table 54. World Postmenopausal Vaginal Atrophy Drugs Production Value by Application, (USD Million), 2018 & 2022 & 2029
Table 55. World Postmenopausal Vaginal Atrophy Drugs Production by Application (2018-2023) & (K Units)
Table 56. World Postmenopausal Vaginal Atrophy Drugs Production by Application (2024-2029) & (K Units)
Table 57. World Postmenopausal Vaginal Atrophy Drugs Production Value by Application (2018-2023) & (USD Million)
Table 58. World Postmenopausal Vaginal Atrophy Drugs Production Value by Application (2024-2029) & (USD Million)
Table 59. World Postmenopausal Vaginal Atrophy Drugs Average Price by Application (2018-2023) & (US$/Unit)
Table 60. World Postmenopausal Vaginal Atrophy Drugs Average Price by Application (2024-2029) & (US$/Unit)
Table 61. Pfizer Inc Basic Information, Manufacturing Base and Competitors
Table 62. Pfizer Inc Major Business
Table 63. Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 64. Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 65. Pfizer Inc Recent Developments/Updates
Table 66. Pfizer Inc Competitive Strengths & Weaknesses
Table 67. Mylan NV Basic Information, Manufacturing Base and Competitors
Table 68. Mylan NV Major Business
Table 69. Mylan NV Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 70. Mylan NV Postmenopausal Vaginal Atrophy Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 71. Mylan NV Recent Developments/Updates
Table 72. Mylan NV Competitive Strengths & Weaknesses
Table 73. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 74. Novartis AG Major Business
Table 75. Novartis AG Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 76. Novartis AG Postmenopausal Vaginal Atrophy Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. Novartis AG Recent Developments/Updates
Table 78. Novartis AG Competitive Strengths & Weaknesses
Table 79. Hikma Pharmaceuticals plc Basic Information, Manufacturing Base and Competitors
Table 80. Hikma Pharmaceuticals plc Major Business
Table 81. Hikma Pharmaceuticals plc Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 82. Hikma Pharmaceuticals plc Postmenopausal Vaginal Atrophy Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 83. Hikma Pharmaceuticals plc Recent Developments/Updates
Table 84. Hikma Pharmaceuticals plc Competitive Strengths & Weaknesses
Table 85. Aurobindo Pharma Basic Information, Manufacturing Base and Competitors
Table 86. Aurobindo Pharma Major Business
Table 87. Aurobindo Pharma Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 88. Aurobindo Pharma Postmenopausal Vaginal Atrophy Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. Aurobindo Pharma Recent Developments/Updates
Table 90. Aurobindo Pharma Competitive Strengths & Weaknesses
Table 91. AbbVie Inc Basic Information, Manufacturing Base and Competitors
Table 92. AbbVie Inc Major Business
Table 93. AbbVie Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 94. AbbVie Inc Postmenopausal Vaginal Atrophy Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 95. AbbVie Inc Recent Developments/Updates
Table 96. AbbVie Inc Competitive Strengths & Weaknesses
Table 97. Melinta Therapeutics, Inc Basic Information, Manufacturing Base and Competitors
Table 98. Melinta Therapeutics, Inc Major Business
Table 99. Melinta Therapeutics, Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 100. Melinta Therapeutics, Inc Postmenopausal Vaginal Atrophy Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 101. Melinta Therapeutics, Inc Recent Developments/Updates
Table 102. Melinta Therapeutics, Inc Competitive Strengths & Weaknesses
Table 103. Bristol-Myers Squibb Company Basic Information, Manufacturing Base and Competitors
Table 104. Bristol-Myers Squibb Company Major Business
Table 105. Bristol-Myers Squibb Company Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 106. Bristol-Myers Squibb Company Postmenopausal Vaginal Atrophy Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 107. Bristol-Myers Squibb Company Recent Developments/Updates
Table 108. Bristol-Myers Squibb Company Competitive Strengths & Weaknesses
Table 109. GSK plc Basic Information, Manufacturing Base and Competitors
Table 110. GSK plc Major Business
Table 111. GSK plc Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 112. GSK plc Postmenopausal Vaginal Atrophy Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 113. GSK plc Recent Developments/Updates
Table 114. GSK plc Competitive Strengths & Weaknesses
Table 115. Bayer AG Basic Information, Manufacturing Base and Competitors
Table 116. Bayer AG Major Business
Table 117. Bayer AG Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 118. Bayer AG Postmenopausal Vaginal Atrophy Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 119. Bayer AG Recent Developments/Updates
Table 120. Bayer AG Competitive Strengths & Weaknesses
Table 121. Lupin Basic Information, Manufacturing Base and Competitors
Table 122. Lupin Major Business
Table 123. Lupin Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 124. Lupin Postmenopausal Vaginal Atrophy Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 125. Lupin Recent Developments/Updates
Table 126. Lupin Competitive Strengths & Weaknesses
Table 127. Perrigo Company plc Basic Information, Manufacturing Base and Competitors
Table 128. Perrigo Company plc Major Business
Table 129. Perrigo Company plc Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 130. Perrigo Company plc Postmenopausal Vaginal Atrophy Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 131. Perrigo Company plc Recent Developments/Updates
Table 132. Perrigo Company plc Competitive Strengths & Weaknesses
Table 133. Bionovo, Inc Basic Information, Manufacturing Base and Competitors
Table 134. Bionovo, Inc Major Business
Table 135. Bionovo, Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 136. Bionovo, Inc Postmenopausal Vaginal Atrophy Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 137. Bionovo, Inc Recent Developments/Updates
Table 138. Bionovo, Inc Competitive Strengths & Weaknesses
Table 139. TherapeuticsMD, Inc Basic Information, Manufacturing Base and Competitors
Table 140. TherapeuticsMD, Inc Major Business
Table 141. TherapeuticsMD, Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 142. TherapeuticsMD, Inc Postmenopausal Vaginal Atrophy Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 143. TherapeuticsMD, Inc Recent Developments/Updates
Table 144. Endoceutics, Inc Basic Information, Manufacturing Base and Competitors
Table 145. Endoceutics, Inc Major Business
Table 146. Endoceutics, Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 147. Endoceutics, Inc Postmenopausal Vaginal Atrophy Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 148. Global Key Players of Postmenopausal Vaginal Atrophy Drugs Upstream (Raw Materials)
Table 149. Postmenopausal Vaginal Atrophy Drugs Typical Customers
Table 150. Postmenopausal Vaginal Atrophy Drugs Typical Distributors
Table 1. World Postmenopausal Vaginal Atrophy Drugs Production Value by Region (2018, 2022 and 2029) & (USD Million)
Table 2. World Postmenopausal Vaginal Atrophy Drugs Production Value by Region (2018-2023) & (USD Million)
Table 3. World Postmenopausal Vaginal Atrophy Drugs Production Value by Region (2024-2029) & (USD Million)
Table 4. World Postmenopausal Vaginal Atrophy Drugs Production Value Market Share by Region (2018-2023)
Table 5. World Postmenopausal Vaginal Atrophy Drugs Production Value Market Share by Region (2024-2029)
Table 6. World Postmenopausal Vaginal Atrophy Drugs Production by Region (2018-2023) & (K Units)
Table 7. World Postmenopausal Vaginal Atrophy Drugs Production by Region (2024-2029) & (K Units)
Table 8. World Postmenopausal Vaginal Atrophy Drugs Production Market Share by Region (2018-2023)
Table 9. World Postmenopausal Vaginal Atrophy Drugs Production Market Share by Region (2024-2029)
Table 10. World Postmenopausal Vaginal Atrophy Drugs Average Price by Region (2018-2023) & (US$/Unit)
Table 11. World Postmenopausal Vaginal Atrophy Drugs Average Price by Region (2024-2029) & (US$/Unit)
Table 12. Postmenopausal Vaginal Atrophy Drugs Major Market Trends
Table 13. World Postmenopausal Vaginal Atrophy Drugs Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)
Table 14. World Postmenopausal Vaginal Atrophy Drugs Consumption by Region (2018-2023) & (K Units)
Table 15. World Postmenopausal Vaginal Atrophy Drugs Consumption Forecast by Region (2024-2029) & (K Units)
Table 16. World Postmenopausal Vaginal Atrophy Drugs Production Value by Manufacturer (2018-2023) & (USD Million)
Table 17. Production Value Market Share of Key Postmenopausal Vaginal Atrophy Drugs Producers in 2022
Table 18. World Postmenopausal Vaginal Atrophy Drugs Production by Manufacturer (2018-2023) & (K Units)
Table 19. Production Market Share of Key Postmenopausal Vaginal Atrophy Drugs Producers in 2022
Table 20. World Postmenopausal Vaginal Atrophy Drugs Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 21. Global Postmenopausal Vaginal Atrophy Drugs Company Evaluation Quadrant
Table 22. World Postmenopausal Vaginal Atrophy Drugs Industry Rank of Major Manufacturers, Based on Production Value in 2022
Table 23. Head Office and Postmenopausal Vaginal Atrophy Drugs Production Site of Key Manufacturer
Table 24. Postmenopausal Vaginal Atrophy Drugs Market: Company Product Type Footprint
Table 25. Postmenopausal Vaginal Atrophy Drugs Market: Company Product Application Footprint
Table 26. Postmenopausal Vaginal Atrophy Drugs Competitive Factors
Table 27. Postmenopausal Vaginal Atrophy Drugs New Entrant and Capacity Expansion Plans
Table 28. Postmenopausal Vaginal Atrophy Drugs Mergers & Acquisitions Activity
Table 29. United States VS China Postmenopausal Vaginal Atrophy Drugs Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 30. United States VS China Postmenopausal Vaginal Atrophy Drugs Production Comparison, (2018 & 2022 & 2029) & (K Units)
Table 31. United States VS China Postmenopausal Vaginal Atrophy Drugs Consumption Comparison, (2018 & 2022 & 2029) & (K Units)
Table 32. United States Based Postmenopausal Vaginal Atrophy Drugs Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Postmenopausal Vaginal Atrophy Drugs Production Value, (2018-2023) & (USD Million)
Table 34. United States Based Manufacturers Postmenopausal Vaginal Atrophy Drugs Production Value Market Share (2018-2023)
Table 35. United States Based Manufacturers Postmenopausal Vaginal Atrophy Drugs Production (2018-2023) & (K Units)
Table 36. United States Based Manufacturers Postmenopausal Vaginal Atrophy Drugs Production Market Share (2018-2023)
Table 37. China Based Postmenopausal Vaginal Atrophy Drugs Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Postmenopausal Vaginal Atrophy Drugs Production Value, (2018-2023) & (USD Million)
Table 39. China Based Manufacturers Postmenopausal Vaginal Atrophy Drugs Production Value Market Share (2018-2023)
Table 40. China Based Manufacturers Postmenopausal Vaginal Atrophy Drugs Production (2018-2023) & (K Units)
Table 41. China Based Manufacturers Postmenopausal Vaginal Atrophy Drugs Production Market Share (2018-2023)
Table 42. Rest of World Based Postmenopausal Vaginal Atrophy Drugs Manufacturers, Headquarters and Production Site (States, Country)
Table 43. Rest of World Based Manufacturers Postmenopausal Vaginal Atrophy Drugs Production Value, (2018-2023) & (USD Million)
Table 44. Rest of World Based Manufacturers Postmenopausal Vaginal Atrophy Drugs Production Value Market Share (2018-2023)
Table 45. Rest of World Based Manufacturers Postmenopausal Vaginal Atrophy Drugs Production (2018-2023) & (K Units)
Table 46. Rest of World Based Manufacturers Postmenopausal Vaginal Atrophy Drugs Production Market Share (2018-2023)
Table 47. World Postmenopausal Vaginal Atrophy Drugs Production Value by Type, (USD Million), 2018 & 2022 & 2029
Table 48. World Postmenopausal Vaginal Atrophy Drugs Production by Type (2018-2023) & (K Units)
Table 49. World Postmenopausal Vaginal Atrophy Drugs Production by Type (2024-2029) & (K Units)
Table 50. World Postmenopausal Vaginal Atrophy Drugs Production Value by Type (2018-2023) & (USD Million)
Table 51. World Postmenopausal Vaginal Atrophy Drugs Production Value by Type (2024-2029) & (USD Million)
Table 52. World Postmenopausal Vaginal Atrophy Drugs Average Price by Type (2018-2023) & (US$/Unit)
Table 53. World Postmenopausal Vaginal Atrophy Drugs Average Price by Type (2024-2029) & (US$/Unit)
Table 54. World Postmenopausal Vaginal Atrophy Drugs Production Value by Application, (USD Million), 2018 & 2022 & 2029
Table 55. World Postmenopausal Vaginal Atrophy Drugs Production by Application (2018-2023) & (K Units)
Table 56. World Postmenopausal Vaginal Atrophy Drugs Production by Application (2024-2029) & (K Units)
Table 57. World Postmenopausal Vaginal Atrophy Drugs Production Value by Application (2018-2023) & (USD Million)
Table 58. World Postmenopausal Vaginal Atrophy Drugs Production Value by Application (2024-2029) & (USD Million)
Table 59. World Postmenopausal Vaginal Atrophy Drugs Average Price by Application (2018-2023) & (US$/Unit)
Table 60. World Postmenopausal Vaginal Atrophy Drugs Average Price by Application (2024-2029) & (US$/Unit)
Table 61. Pfizer Inc Basic Information, Manufacturing Base and Competitors
Table 62. Pfizer Inc Major Business
Table 63. Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 64. Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 65. Pfizer Inc Recent Developments/Updates
Table 66. Pfizer Inc Competitive Strengths & Weaknesses
Table 67. Mylan NV Basic Information, Manufacturing Base and Competitors
Table 68. Mylan NV Major Business
Table 69. Mylan NV Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 70. Mylan NV Postmenopausal Vaginal Atrophy Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 71. Mylan NV Recent Developments/Updates
Table 72. Mylan NV Competitive Strengths & Weaknesses
Table 73. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 74. Novartis AG Major Business
Table 75. Novartis AG Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 76. Novartis AG Postmenopausal Vaginal Atrophy Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. Novartis AG Recent Developments/Updates
Table 78. Novartis AG Competitive Strengths & Weaknesses
Table 79. Hikma Pharmaceuticals plc Basic Information, Manufacturing Base and Competitors
Table 80. Hikma Pharmaceuticals plc Major Business
Table 81. Hikma Pharmaceuticals plc Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 82. Hikma Pharmaceuticals plc Postmenopausal Vaginal Atrophy Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 83. Hikma Pharmaceuticals plc Recent Developments/Updates
Table 84. Hikma Pharmaceuticals plc Competitive Strengths & Weaknesses
Table 85. Aurobindo Pharma Basic Information, Manufacturing Base and Competitors
Table 86. Aurobindo Pharma Major Business
Table 87. Aurobindo Pharma Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 88. Aurobindo Pharma Postmenopausal Vaginal Atrophy Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. Aurobindo Pharma Recent Developments/Updates
Table 90. Aurobindo Pharma Competitive Strengths & Weaknesses
Table 91. AbbVie Inc Basic Information, Manufacturing Base and Competitors
Table 92. AbbVie Inc Major Business
Table 93. AbbVie Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 94. AbbVie Inc Postmenopausal Vaginal Atrophy Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 95. AbbVie Inc Recent Developments/Updates
Table 96. AbbVie Inc Competitive Strengths & Weaknesses
Table 97. Melinta Therapeutics, Inc Basic Information, Manufacturing Base and Competitors
Table 98. Melinta Therapeutics, Inc Major Business
Table 99. Melinta Therapeutics, Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 100. Melinta Therapeutics, Inc Postmenopausal Vaginal Atrophy Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 101. Melinta Therapeutics, Inc Recent Developments/Updates
Table 102. Melinta Therapeutics, Inc Competitive Strengths & Weaknesses
Table 103. Bristol-Myers Squibb Company Basic Information, Manufacturing Base and Competitors
Table 104. Bristol-Myers Squibb Company Major Business
Table 105. Bristol-Myers Squibb Company Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 106. Bristol-Myers Squibb Company Postmenopausal Vaginal Atrophy Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 107. Bristol-Myers Squibb Company Recent Developments/Updates
Table 108. Bristol-Myers Squibb Company Competitive Strengths & Weaknesses
Table 109. GSK plc Basic Information, Manufacturing Base and Competitors
Table 110. GSK plc Major Business
Table 111. GSK plc Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 112. GSK plc Postmenopausal Vaginal Atrophy Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 113. GSK plc Recent Developments/Updates
Table 114. GSK plc Competitive Strengths & Weaknesses
Table 115. Bayer AG Basic Information, Manufacturing Base and Competitors
Table 116. Bayer AG Major Business
Table 117. Bayer AG Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 118. Bayer AG Postmenopausal Vaginal Atrophy Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 119. Bayer AG Recent Developments/Updates
Table 120. Bayer AG Competitive Strengths & Weaknesses
Table 121. Lupin Basic Information, Manufacturing Base and Competitors
Table 122. Lupin Major Business
Table 123. Lupin Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 124. Lupin Postmenopausal Vaginal Atrophy Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 125. Lupin Recent Developments/Updates
Table 126. Lupin Competitive Strengths & Weaknesses
Table 127. Perrigo Company plc Basic Information, Manufacturing Base and Competitors
Table 128. Perrigo Company plc Major Business
Table 129. Perrigo Company plc Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 130. Perrigo Company plc Postmenopausal Vaginal Atrophy Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 131. Perrigo Company plc Recent Developments/Updates
Table 132. Perrigo Company plc Competitive Strengths & Weaknesses
Table 133. Bionovo, Inc Basic Information, Manufacturing Base and Competitors
Table 134. Bionovo, Inc Major Business
Table 135. Bionovo, Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 136. Bionovo, Inc Postmenopausal Vaginal Atrophy Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 137. Bionovo, Inc Recent Developments/Updates
Table 138. Bionovo, Inc Competitive Strengths & Weaknesses
Table 139. TherapeuticsMD, Inc Basic Information, Manufacturing Base and Competitors
Table 140. TherapeuticsMD, Inc Major Business
Table 141. TherapeuticsMD, Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 142. TherapeuticsMD, Inc Postmenopausal Vaginal Atrophy Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 143. TherapeuticsMD, Inc Recent Developments/Updates
Table 144. Endoceutics, Inc Basic Information, Manufacturing Base and Competitors
Table 145. Endoceutics, Inc Major Business
Table 146. Endoceutics, Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 147. Endoceutics, Inc Postmenopausal Vaginal Atrophy Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 148. Global Key Players of Postmenopausal Vaginal Atrophy Drugs Upstream (Raw Materials)
Table 149. Postmenopausal Vaginal Atrophy Drugs Typical Customers
Table 150. Postmenopausal Vaginal Atrophy Drugs Typical Distributors
LIST OF FIGURES
Figure 1. Postmenopausal Vaginal Atrophy Drugs Picture
Figure 2. World Postmenopausal Vaginal Atrophy Drugs Production Value: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Postmenopausal Vaginal Atrophy Drugs Production Value and Forecast (2018-2029) & (USD Million)
Figure 4. World Postmenopausal Vaginal Atrophy Drugs Production (2018-2029) & (K Units)
Figure 5. World Postmenopausal Vaginal Atrophy Drugs Average Price (2018-2029) & (US$/Unit)
Figure 6. World Postmenopausal Vaginal Atrophy Drugs Production Value Market Share by Region (2018-2029)
Figure 7. World Postmenopausal Vaginal Atrophy Drugs Production Market Share by Region (2018-2029)
Figure 8. North America Postmenopausal Vaginal Atrophy Drugs Production (2018-2029) & (K Units)
Figure 9. Europe Postmenopausal Vaginal Atrophy Drugs Production (2018-2029) & (K Units)
Figure 10. China Postmenopausal Vaginal Atrophy Drugs Production (2018-2029) & (K Units)
Figure 11. Japan Postmenopausal Vaginal Atrophy Drugs Production (2018-2029) & (K Units)
Figure 12. Postmenopausal Vaginal Atrophy Drugs Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Postmenopausal Vaginal Atrophy Drugs Consumption (2018-2029) & (K Units)
Figure 15. World Postmenopausal Vaginal Atrophy Drugs Consumption Market Share by Region (2018-2029)
Figure 16. United States Postmenopausal Vaginal Atrophy Drugs Consumption (2018-2029) & (K Units)
Figure 17. China Postmenopausal Vaginal Atrophy Drugs Consumption (2018-2029) & (K Units)
Figure 18. Europe Postmenopausal Vaginal Atrophy Drugs Consumption (2018-2029) & (K Units)
Figure 19. Japan Postmenopausal Vaginal Atrophy Drugs Consumption (2018-2029) & (K Units)
Figure 20. South Korea Postmenopausal Vaginal Atrophy Drugs Consumption (2018-2029) & (K Units)
Figure 21. ASEAN Postmenopausal Vaginal Atrophy Drugs Consumption (2018-2029) & (K Units)
Figure 22. India Postmenopausal Vaginal Atrophy Drugs Consumption (2018-2029) & (K Units)
Figure 23. Producer Shipments of Postmenopausal Vaginal Atrophy Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2022
Figure 24. Global Four-firm Concentration Ratios (CR4) for Postmenopausal Vaginal Atrophy Drugs Markets in 2022
Figure 25. Global Four-firm Concentration Ratios (CR8) for Postmenopausal Vaginal Atrophy Drugs Markets in 2022
Figure 26. United States VS China: Postmenopausal Vaginal Atrophy Drugs Production Value Market Share Comparison (2018 & 2022 & 2029)
Figure 27. United States VS China: Postmenopausal Vaginal Atrophy Drugs Production Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Postmenopausal Vaginal Atrophy Drugs Consumption Market Share Comparison (2018 & 2022 & 2029)
Figure 29. United States Based Manufacturers Postmenopausal Vaginal Atrophy Drugs Production Market Share 2022
Figure 30. China Based Manufacturers Postmenopausal Vaginal Atrophy Drugs Production Market Share 2022
Figure 31. Rest of World Based Manufacturers Postmenopausal Vaginal Atrophy Drugs Production Market Share 2022
Figure 32. World Postmenopausal Vaginal Atrophy Drugs Production Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 33. World Postmenopausal Vaginal Atrophy Drugs Production Value Market Share by Type in 2022
Figure 34. Topical Estrogen
Figure 35. Oral Estrogen
Figure 36. Other
Figure 37. World Postmenopausal Vaginal Atrophy Drugs Production Market Share by Type (2018-2029)
Figure 38. World Postmenopausal Vaginal Atrophy Drugs Production Value Market Share by Type (2018-2029)
Figure 39. World Postmenopausal Vaginal Atrophy Drugs Average Price by Type (2018-2029) & (US$/Unit)
Figure 40. World Postmenopausal Vaginal Atrophy Drugs Production Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 41. World Postmenopausal Vaginal Atrophy Drugs Production Value Market Share by Application in 2022
Figure 42. Online Pharmacy
Figure 43. Hospital Pharmacy
Figure 44. World Postmenopausal Vaginal Atrophy Drugs Production Market Share by Application (2018-2029)
Figure 45. World Postmenopausal Vaginal Atrophy Drugs Production Value Market Share by Application (2018-2029)
Figure 46. World Postmenopausal Vaginal Atrophy Drugs Average Price by Application (2018-2029) & (US$/Unit)
Figure 47. Postmenopausal Vaginal Atrophy Drugs Industry Chain
Figure 48. Postmenopausal Vaginal Atrophy Drugs Procurement Model
Figure 49. Postmenopausal Vaginal Atrophy Drugs Sales Model
Figure 50. Postmenopausal Vaginal Atrophy Drugs Sales Channels, Direct Sales, and Distribution
Figure 51. Methodology
Figure 52. Research Process and Data Source
Figure 1. Postmenopausal Vaginal Atrophy Drugs Picture
Figure 2. World Postmenopausal Vaginal Atrophy Drugs Production Value: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Postmenopausal Vaginal Atrophy Drugs Production Value and Forecast (2018-2029) & (USD Million)
Figure 4. World Postmenopausal Vaginal Atrophy Drugs Production (2018-2029) & (K Units)
Figure 5. World Postmenopausal Vaginal Atrophy Drugs Average Price (2018-2029) & (US$/Unit)
Figure 6. World Postmenopausal Vaginal Atrophy Drugs Production Value Market Share by Region (2018-2029)
Figure 7. World Postmenopausal Vaginal Atrophy Drugs Production Market Share by Region (2018-2029)
Figure 8. North America Postmenopausal Vaginal Atrophy Drugs Production (2018-2029) & (K Units)
Figure 9. Europe Postmenopausal Vaginal Atrophy Drugs Production (2018-2029) & (K Units)
Figure 10. China Postmenopausal Vaginal Atrophy Drugs Production (2018-2029) & (K Units)
Figure 11. Japan Postmenopausal Vaginal Atrophy Drugs Production (2018-2029) & (K Units)
Figure 12. Postmenopausal Vaginal Atrophy Drugs Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Postmenopausal Vaginal Atrophy Drugs Consumption (2018-2029) & (K Units)
Figure 15. World Postmenopausal Vaginal Atrophy Drugs Consumption Market Share by Region (2018-2029)
Figure 16. United States Postmenopausal Vaginal Atrophy Drugs Consumption (2018-2029) & (K Units)
Figure 17. China Postmenopausal Vaginal Atrophy Drugs Consumption (2018-2029) & (K Units)
Figure 18. Europe Postmenopausal Vaginal Atrophy Drugs Consumption (2018-2029) & (K Units)
Figure 19. Japan Postmenopausal Vaginal Atrophy Drugs Consumption (2018-2029) & (K Units)
Figure 20. South Korea Postmenopausal Vaginal Atrophy Drugs Consumption (2018-2029) & (K Units)
Figure 21. ASEAN Postmenopausal Vaginal Atrophy Drugs Consumption (2018-2029) & (K Units)
Figure 22. India Postmenopausal Vaginal Atrophy Drugs Consumption (2018-2029) & (K Units)
Figure 23. Producer Shipments of Postmenopausal Vaginal Atrophy Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2022
Figure 24. Global Four-firm Concentration Ratios (CR4) for Postmenopausal Vaginal Atrophy Drugs Markets in 2022
Figure 25. Global Four-firm Concentration Ratios (CR8) for Postmenopausal Vaginal Atrophy Drugs Markets in 2022
Figure 26. United States VS China: Postmenopausal Vaginal Atrophy Drugs Production Value Market Share Comparison (2018 & 2022 & 2029)
Figure 27. United States VS China: Postmenopausal Vaginal Atrophy Drugs Production Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Postmenopausal Vaginal Atrophy Drugs Consumption Market Share Comparison (2018 & 2022 & 2029)
Figure 29. United States Based Manufacturers Postmenopausal Vaginal Atrophy Drugs Production Market Share 2022
Figure 30. China Based Manufacturers Postmenopausal Vaginal Atrophy Drugs Production Market Share 2022
Figure 31. Rest of World Based Manufacturers Postmenopausal Vaginal Atrophy Drugs Production Market Share 2022
Figure 32. World Postmenopausal Vaginal Atrophy Drugs Production Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 33. World Postmenopausal Vaginal Atrophy Drugs Production Value Market Share by Type in 2022
Figure 34. Topical Estrogen
Figure 35. Oral Estrogen
Figure 36. Other
Figure 37. World Postmenopausal Vaginal Atrophy Drugs Production Market Share by Type (2018-2029)
Figure 38. World Postmenopausal Vaginal Atrophy Drugs Production Value Market Share by Type (2018-2029)
Figure 39. World Postmenopausal Vaginal Atrophy Drugs Average Price by Type (2018-2029) & (US$/Unit)
Figure 40. World Postmenopausal Vaginal Atrophy Drugs Production Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 41. World Postmenopausal Vaginal Atrophy Drugs Production Value Market Share by Application in 2022
Figure 42. Online Pharmacy
Figure 43. Hospital Pharmacy
Figure 44. World Postmenopausal Vaginal Atrophy Drugs Production Market Share by Application (2018-2029)
Figure 45. World Postmenopausal Vaginal Atrophy Drugs Production Value Market Share by Application (2018-2029)
Figure 46. World Postmenopausal Vaginal Atrophy Drugs Average Price by Application (2018-2029) & (US$/Unit)
Figure 47. Postmenopausal Vaginal Atrophy Drugs Industry Chain
Figure 48. Postmenopausal Vaginal Atrophy Drugs Procurement Model
Figure 49. Postmenopausal Vaginal Atrophy Drugs Sales Model
Figure 50. Postmenopausal Vaginal Atrophy Drugs Sales Channels, Direct Sales, and Distribution
Figure 51. Methodology
Figure 52. Research Process and Data Source
